AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1577054 — intervention group
Group type: EXPERIMENTAL
Intervention: DuP-753 100 mg (multiple doses)
Number of subjects: 21
Study 1577054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3900800 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrol
Number of subjects: 100
Study 3900800 — intervention group
Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 100
Study 3900800 — intervention group
Group type: COMPARATOR
Intervention: iopamidol
Number of subjects: 100
Study 3301683 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of anti-lipid A
Number of subjects: 17
Study 3301683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 17
Study 30172572 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-enabled nurse coaching intervention
Number of subjects: 132
Study 29871286 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tympanic membrane surgical knife with suction and tube device
Number of subjects: 87
Study 29871286 — intervention group
Group type: COMPARATOR
Intervention: General approach for tympanic membrane tube insertion
Number of subjects: 87
Study 26172395 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1800 mg orally for 4 months
Number of subjects: 66
Study 26172395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 23238789 — intervention group
Group type: EXPERIMENTAL
Intervention: FREMS
Number of subjects: 110
Study 21944176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 200
Study 21944176 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 200
Study 18721823 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate-flavored dairy drink
Number of subjects: 2
Study 18721823 — intervention group
Group type: COMPARATOR
Intervention: Chocolate-flavored dairy semi-solid
Number of subjects: 2
Study 16846541 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide HFA pMDI 200 mug twice daily
Number of subjects: 159
Study 16846541 — intervention group
Group type: COMPARATOR
Intervention: Budesonide CFC pMDI 200 mug twice daily
Number of subjects: 159
Study 16846541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both budesonide formulations (HFA and CFC)
Number of subjects: 159
Study 11870012 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 85
Study 11870012 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 85
Study 11870012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 10465472 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (XRT)
Number of subjects: 75
Study 10465472 — intervention group
Group type: COMPARATOR
Intervention: Endobronchial treatment (brachytherapy, laser resection, or cryotherapy)
Number of subjects: 75
Study 7840053 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of epoprostenol plus conventional therapy
Number of subjects: 33
Study 7840053 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 33
Study 2369312 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited incision (muscle-sparing thoracotomy)
Number of subjects: 28
Study 2369312 — intervention group
Group type: COMPARATOR
Intervention: Standard thoracotomy
Number of subjects: 28
Study 627191 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheomacrodex 10%
Number of subjects: 54
Study 627191 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (physiological saline)
Number of subjects: 54
Study 29679844 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairment Rating Scale‐ADHD
Number of subjects: 107
Study 29679844 — intervention group
Group type: COMPARATOR
Intervention: Standard Impairment Rating Scale
Number of subjects: 107
Study 26395438 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally supervised exercise program
Number of subjects: 231
Study 26395438 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 231
Study 24838056 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-septal lead position
Number of subjects: 299
Study 24838056 — intervention group
Group type: COMPARATOR
Intervention: Apical lead position
Number of subjects: 299
Study 22624834 — intervention group
Group type: EXPERIMENTAL
Intervention: J-wave in patients with idiopathic VF
Number of subjects: 40
Study 22624834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pause-dependent augmentation of J waves during storms of VF
Number of subjects: 40
Study 22624834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pause-dependent augmentation of J waves after sudden R-R prolongation
Number of subjects: 40
Study 22624834 — intervention group
Group type: COMPARATOR
Intervention: J waves in control subjects
Number of subjects: 40
Study 22624834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pause-dependent augmentation of J waves
Number of subjects: 40
Study 21491007 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond Moisture Insensitive Primer
Number of subjects: 45
Study 21491007 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond
Number of subjects: 45
Study 21491007 — intervention group
Group type: COMPARATOR
Intervention: Conventional Transbond XT primer
Number of subjects: 45
Study 18524974 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol-270 (60 mL intravenous bolus)
Number of subjects: 100
Study 18524974 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iodinated contrast media)
Number of subjects: 100
Study 16632399 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CT) with radiation therapy (RT) - mitoxantrone (12 mg/m2), 5-FU (500 mg/m2), cyclophosphamide (500 mg/m2), 6 cycles, first 3 cycles of CT with RT
Number of subjects: 214
Study 16632399 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy (CT) followed by radiation therapy (RT) - mitoxantrone (12 mg/m2), 5-FU (500 mg/m2), cyclophosphamide (500 mg/m2), 6 cycles, RT started 3 to 5 weeks after the 6th cycle of CT
Number of subjects: 214
Study 14653835 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg
Number of subjects: 18
Study 14653835 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 18
Study 14653835 — intervention group
Group type: EXPERIMENTAL
Intervention: Lafutidine 20 mg
Number of subjects: 18
Study 14653835 — intervention group
Group type: COMPARATOR
Intervention: Water only (baseline data)
Number of subjects: 18
Study 10228604 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinaforce (Echinacea purpurea-preparation from 95% herba and 5% radix)
Number of subjects: 246
Study 10228604 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea concentrate (7 times higher concentration)
Number of subjects: 246
Study 10228604 — intervention group
Group type: COMPARATOR
Intervention: Special Echinacea purpurea radix preparation
Number of subjects: 246
Study 10228604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 8904594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal inhalation of cold dry air (‐4 degrees C)
Number of subjects: 0
Study 8904594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal inhalation of cold dry air (‐10 degrees C)
Number of subjects: 0
Study 8904594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal inhalation of dry air (0.3% RH)
Number of subjects: 0
Study 8904594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal inhalation of moist room air (97% RH)
Number of subjects: 0
Study 8904594 — intervention group
Group type: COMPARATOR
Intervention: Oral breathing of cold dry air, dry air, or moist air
Number of subjects: 0
Study 8904594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal anesthesia or inhalation of a cholinergic antagonist before cold air
Number of subjects: 0
Study 1930699 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 226
Study 1930699 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 226
Study 1930699 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 650 mg with codeine 60 mg
Number of subjects: 226
Study 1930699 — intervention group
Group type: COMPARATOR
Intervention: Zomepirac sodium 100 mg
Number of subjects: 226
Study 1930699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 7126493 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 5
Study 7126493 — intervention group
Group type: COMPARATOR
Intervention: Insight-oriented therapy
Number of subjects: 5
Study 31029475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac-soaked bandage contact lens
Number of subjects: 70
Study 31029475 — intervention group
Group type: COMPARATOR
Intervention: Regular soft bandage contact lens
Number of subjects: 70
Study 29604620 — intervention group
Group type: EXPERIMENTAL
Intervention: Caricol®-Gastro (20 g, taken twice per day for 30 days)
Number of subjects: 60
Study 29604620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27542921 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified atWork intervention
Number of subjects: 1100
Study 27542921 — intervention group
Group type: COMPARATOR
Intervention: Original atWork intervention
Number of subjects: 1100
Study 23925644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone±salmeterol
Number of subjects: 89
Study 23373239 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled synechiae technique
Number of subjects: 86
Study 23373239 — intervention group
Group type: COMPARATOR
Intervention: Extended nasal packing in middle meatus until 1 week after surgery
Number of subjects: 86
Study 20574204 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practice (EBP) implementation
Number of subjects: 0
Study 18564687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DTPw‐HBV/Hib vaccine administered at 1.5, 3, and 5 months after a birth dose of hepatitis B vaccine (HBV)
Number of subjects: 0
Study 18564687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DTPw‐HBV/Hib vaccine
Number of subjects: 0
Study 15958628 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat 5 mg
Number of subjects: 39
Study 15958628 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat 20 mg
Number of subjects: 39
Study 15958628 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat 40 mg
Number of subjects: 39
Study 15958628 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat (all doses)
Number of subjects: 39
Study 14633146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 38
Study 14633146 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis
Number of subjects: 38
Study 14633146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis vs Peritoneal dialysis
Number of subjects: 38
Study 14633146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis vs Peritoneal dialysis (adjusted)
Number of subjects: 38
Study 10501821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPF) 600 mg t.i.d.
Number of subjects: 12
Study 8865551 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasound measurements at three visits, 7-14 days apart.
Number of subjects: 36
Study 8865551 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted B-mode ultrasound measurements for site-specific reliability coefficients.
Number of subjects: 36
Study 1510258 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge Quincke needle (n = 147)
Number of subjects: 298
Study 1510258 — intervention group
Group type: COMPARATOR
Intervention: 24-gauge Sprotte needle (n = 151)
Number of subjects: 298
Study 6423871 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction group (received phenobarbital and glutathione)
Number of subjects: 207
Study 6423871 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction group
Number of subjects: 207
Study 6423871 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 207
Study 31415787 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium oxalate 10%
Number of subjects: 31
Study 31415787 — intervention group
Group type: COMPARATOR
Intervention: Potassium oxalate 5%
Number of subjects: 31
Study 30499486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresonance therapy (BRT)
Number of subjects: 60
Study 30499486 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedures (control)
Number of subjects: 60
Study 27255927 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher praise and reprimands during regular classroom lessons
Number of subjects: 570
Study 27255927 — intervention group
Group type: COMPARATOR
Intervention: Good Behavior Game (GBG) implemented in half of the classrooms
Number of subjects: 570
Study 24589870 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) as a coping strategy for smoking cessation
Number of subjects: 799
Study 21983265 — intervention group
Group type: EXPERIMENTAL
Intervention: KRN5500
Number of subjects: 19
Study 21983265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 19887157 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumble strips on both sides of the centerline
Number of subjects: 0
Study 19887157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed shoulders
Number of subjects: 0
Study 19887157 — intervention group
Group type: COMPARATOR
Intervention: Current marking system (continuous lines)
Number of subjects: 0
Study 17628912 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 0.6 mg/day (n=8) or methylprednisolone 4 mg/day (n=6), single daily oral dose at 11.00 PM for 30 days
Number of subjects: 28
Study 17628912 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 0.3 mg, single daily dose at 11.00 PM for six months
Number of subjects: 28
Study 17628912 — intervention group
Group type: COMPARATOR
Intervention: Control group (seven normal females)
Number of subjects: 28
Study 17628912 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment evaluation of 11 patients after therapy withdrawal
Number of subjects: 28
Study 16149685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, tid ac for 2 weeks)
Number of subjects: 35
Study 12115016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide suspension 1.5 mg/kg per dose
Number of subjects: 60
Study 12115016 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 60
Study 10399795 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid therapy
Number of subjects: 80
Study 10399795 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral compression fractures
Number of subjects: 80
Study 7960533 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL monotherapy
Number of subjects: 43
Study 7960533 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL+PCNL combined therapy
Number of subjects: 43
Study 7960533 — intervention group
Group type: EXPERIMENTAL
Intervention: Open stone surgery
Number of subjects: 43
Study 3149152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (150 mg, 75 mg twice daily)
Number of subjects: 139
Study 3149152 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (3.6 g, 1.2 g three times daily)
Number of subjects: 139
Study 3149152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 139
Study 3149152 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 139
Study 31326310 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of mild emphysema
Number of subjects: 200
Study 31326310 — intervention group
Group type: COMPARATOR
Intervention: Quantitative densitometric measurements
Number of subjects: 200
Study 29741798 — intervention group
Group type: EXPERIMENTAL
Intervention: CARRII (Contraception and Alcohol Risk Reduction Internet Intervention)
Number of subjects: 71
Study 29741798 — intervention group
Group type: COMPARATOR
Intervention: PE (static patient education website)
Number of subjects: 71
Study 26830642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 26830642 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40
Study 24847666 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast skipping
Number of subjects: 8
Study 24847666 — intervention group
Group type: COMPARATOR
Intervention: Control (with breakfast)
Number of subjects: 8
Study 21975467 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured goal elicitation using the Canadian Occupational Performance Measure
Number of subjects: 41
Study 21975467 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 41
Study 20554596 — intervention group
Group type: EXPERIMENTAL
Intervention: Postgraduate training (completed pharmacy residency or fellowship)
Number of subjects: 1010
Study 20554596 — intervention group
Group type: COMPARATOR
Intervention: No postgraduate training
Number of subjects: 1010
Study 18567822 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (6 weeks administration)
Number of subjects: 20
Study 18567822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 weeks administration)
Number of subjects: 20
Study 15811211 — intervention group
Group type: EXPERIMENTAL
Intervention: gatifloxacin 0.3% administered BID
Number of subjects: 104
Study 15811211 — intervention group
Group type: COMPARATOR
Intervention: gatifloxacin 0.3% administered QID
Number of subjects: 104
Study 11919461 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine hydrochloride gel administered over 10 seconds
Number of subjects: 100
Study 11919461 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine hydrochloride gel administered over 2 seconds
Number of subjects: 100
Study 10632986 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200000 IU)
Number of subjects: 164
Study 10632986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 9120744 — intervention group
Group type: EXPERIMENTAL
Intervention: Curosurf (modified porcine surfactant) administered at birth (80 mg/ml; dose 20 mg/kg)
Number of subjects: 287
Study 9120744 — intervention group
Group type: EXPERIMENTAL
Intervention: Curosurf (modified porcine surfactant) administered at birth
Number of subjects: 287
Study 1712850 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling and support for families of children with intellectual or multiple disabilities
Number of subjects: 0
Study 1712850 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomly allocated)
Number of subjects: 0
Study 6841943 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumide (50 mg/kg bolus, 50 mg/kg hour infusion, 100 mg/kg hour infusion, or combination)
Number of subjects: 3
Study 6841943 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (2 mg/kg I.V. followed by 2 mg/kg hour)
Number of subjects: 3
Study 6841943 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumide and Cimetidine
Number of subjects: 3
Study 31990267 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for detecting infarction on non-contrast-enhanced CT images.
Number of subjects: 100
Study 30664943 — intervention group
Group type: EXPERIMENTAL
Intervention: Working for You multi-level intervention (including iOTA program and workplace participatory program)
Number of subjects: 1000
Study 30664943 — intervention group
Group type: EXPERIMENTAL
Intervention: Working for You multi-level intervention
Number of subjects: 1000
Study 30664943 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1000
Study 28152611 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC intervention (10-session intervention to enhance parent-child interactions)
Number of subjects: 52
Study 28152611 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 52
Study 25565322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency lateral branch neurotomy (CRF/LBN)
Number of subjects: 51
Study 25565322 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (crossover group)
Number of subjects: 51
Study 24362907 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg alpha-lipoic acid (ALA) three times a day orally for 24 weeks
Number of subjects: 243
Study 24362907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 21767449 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (30/0/70 % of energy from protein/carbohydrate/fat)
Number of subjects: 22
Study 21767449 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (12/55/33 % of energy from protein/carbohydrate/fat)
Number of subjects: 22
Study 21767449 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 22
Study 21767449 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet
Number of subjects: 22
Study 19332156 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding group (fluids on the first postoperative day)
Number of subjects: 120
Study 19332156 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding group
Number of subjects: 120
Study 19332156 — intervention group
Group type: COMPARATOR
Intervention: Regular feeding group (nothing by mouth until resolution of ileus)
Number of subjects: 120
Study 19332156 — intervention group
Group type: COMPARATOR
Intervention: Regular feeding group
Number of subjects: 120
Study 17882685 — intervention group
Group type: EXPERIMENTAL
Intervention: New low‐ and ultra‐low‐dose oral preparations (0.3 mg conjugated equine estrogens and 0.5 mg estradiol)
Number of subjects: 0
Study 17882685 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 microg transdermal system
Number of subjects: 0
Study 17882685 — intervention group
Group type: EXPERIMENTAL
Intervention: New progestogens (e.g. drospirenone, bioidentical progesterone, selective progesterone receptor modulators)
Number of subjects: 0
Study 17882685 — intervention group
Group type: EXPERIMENTAL
Intervention: New female androgen patch
Number of subjects: 0
Study 17882685 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate
Number of subjects: 0
Study 17882685 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective estrogen receptor modulator/conjugated equine estrogen preparation combination
Number of subjects: 0